Is it still worth pursuing the repurposing of metformin as a cancer therapeutic?
Citations Over TimeTop 1% of 2023 papers
Abstract
Over the past 15 years, there has been great interest in the potential to repurpose the diabetes drug, metformin, as a cancer treatment. However, despite considerable efforts being made to investigate its efficacy in a number of large randomised clinical trials in different tumour types, results have been disappointing to date. This perspective article summarises how interest initially developed in the oncological potential of metformin and the diverse clinical programme of work to date including our contribution to establishing the intra-tumoral pharmacodynamic effects of metformin in the clinic. We also discuss the lessons that can be learnt from this experience and whether a further clinical investigation of metformin in cancer is warranted.
Related Papers
- → The drug repurposing landscape from 2012 to 2017: evolution, challenges, and possible solutions(2018)113 cited
- → A data-driven methodology towards evaluating the potential of drug repurposing hypotheses(2021)29 cited
- → Treatment Repurposing using Literature-related Discovery(2019)4 cited
- → Drug Repurposing and Multi-Target Therapies(2018)2 cited
- → Faculty Opinions recommendation of Comprehensive Consensus Analysis of SARS-CoV-2 Drug Repurposing Campaigns.(2021)